The objective of this study was therefore to assess, whether pathogenic SMAD6 variants can also be identified in CHD patients with PAH and in a second cohort of idiopathic PAH (IPAH) patients. The gene discussed is SMAD6; the disease is idiopathic pulmonary arterial hypertension.